메뉴 건너뛰기
Clinical Breast Cancer
Volumn 5, Issue SUPPL. 1, 2004, Pages
Current developments in hormonal therapy of breast cancer
Author keywords

[No Author keywords available]
Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ESTRADIOL RECEPTOR; ESTROGEN RECEPTOR; ESTRONE; EXEMESTANE; GESTAGEN; GONADORELIN AGONIST; LETROZOLE; TAMOXIFEN;
EID: 4644314003     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2004.s.007     Document Type: Editorial
Times cited : (1)
References (7)
  • 2
    • 0034669484 scopus 로고    scopus 로고
    • Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in post-menopausal women: Results of a North American multicenter randomised trial
    • Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in post-menopausal women: results of a North American multicenter randomised trial. J Clin Oncol 2000; 18:3758-3776.
    • (2000) J. Clin. Oncol. , vol.18 , pp. 3758-3776
    • Nabholtz, J.M.1    Buzdar, A.2    Pollak, M.3
  • 3
    • 0034669435 scopus 로고    scopus 로고
    • Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women - Results of the TARGET (Tamoxifen or Arimidex™ Randomised Group Efficacy and Tolerability) study
    • Bonneterre J, Thurlimann B, Robertson JFR, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women - results of the TARGET (Tamoxifen or Arimidex™ Randomised Group Efficacy and Tolerability) study. J Clin Oncol 2000; 18:3748-3757.
    • (2000) J. Clin. Oncol. , vol.18 , pp. 3748-3757
    • Bonneterre, J.1    Thurlimann, B.2    Robertson, J.F.R.3
  • 4
    • 0343584508 scopus 로고    scopus 로고
    • Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
    • Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19:2596-2602.
    • (2001) J. Clin. Oncol. , vol.19 , pp. 2596-2602
    • Mouridsen, H.1    Gershanovich, M.2    Sun, Y.3
  • 5
    • 0037157603 scopus 로고    scopus 로고
    • Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial
    • ATAC Trialists' Group
    • ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359:2131-2139.
    • (2002) Lancet , vol.359 , pp. 2131-2139
  • 6
    • 10744223655 scopus 로고    scopus 로고
    • A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
    • Coombes RC, Hall E, Gibson W, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081-l092.
    • (2004) N. Engl. J. Med. , vol.350 , pp. 1081-1092
    • Coombes, R.C.1    Hall, E.2    Gibson, W.3
  • 7
    • 7444259675 scopus 로고    scopus 로고
    • A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    • Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793-1802.
    • (2003) N. Engl. J. Med. , vol.349 , pp. 1793-1802
    • Goss, P.E.1    Ingle, J.N.2    Martino, S.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.